Given that LEDGF is required for menin/MLL to bind chromatin, it is likely that MMF and CX-5461 will be active against MEN1-mutant AML but possibly not against the non-genetic resistant clones. The gene discussed is MEN1; the disease is acute myeloid leukemia.